Dorothy J. Clarke - 01 Jan 2024 Form 4 Insider Report for Eterna Therapeutics Inc. (ERNA)

Reporting relationship: General Counsel, Director
Issuer ticker: ERNA
Reported as of: 01 Jan 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Jan 2024, 17:01:31 UTC
Prior SEC filing: 13 Nov 2023
Source filing: View source filing
Reporting owner signature: /s/ Dorothy Clarke

Key filing fact

Dorothy J. Clarke filed Form 4 for Eterna Therapeutics Inc. (ERNA) on 03 Jan 2024.

Key facts

This page summarizes Dorothy J. Clarke's Form 4 filing for Eterna Therapeutics Inc. (ERNA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 03 Jan 2024, 17:01.

Change

Previous filing in this sequence was filed on 13 Nov 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ERNA transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +168,521
Change %
Price: $0.000000
Shares after: 168,521
Date: 01 Jan 2024
Ownership: Direct
Underlying class: Common Stock, par value $0.005 per share
Underlying amount: 168,521
Exercise price: $1.80
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Subject to continued service, 25% of the shares underlying the stock option will vest on the nine-month anniversary of the grant date, and the remaining shares underlying the stock option will vest in 39 substantially equal monthly installments thereafter.